Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study.

Clin Cancer Res 2017 Jun 15;23(11):2691-2701. Epub 2016 Dec 15.

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland.

In breast cancer models, combination epigenetic therapy with a DNA methyltransferase inhibitor and a histone deacetylase inhibitor led to reexpression of genes encoding important therapeutic targets, including the estrogen receptor (ER). We conducted a multicenter phase II study of 5-azacitidine and entinostat in women with advanced hormone-resistant or triple-negative breast cancer (TNBC). Patients received 5-azacitidine 40 mg/m (days 1-5, 8-10) and entinostat 7 mg (days 3, 10) on a 28-day cycle. Continuation of epigenetic therapy was offered with the addition of endocrine therapy at the time of progression [optional continuation (OC) phase]. Primary endpoint was objective response rate (ORR) in each cohort. We hypothesized that ORR would be ≥20% against null of 5% using Simon two-stage design. At least one response was required in 1 of 13 patients per cohort to continue accrual to 27 per cohort (type I error, 4%; power, 90%). There was one partial response among 27 women with hormone-resistant disease (ORR = 4%; 95% CI, 0-19), and none in 13 women with TNBC. One additional partial response was observed in the OC phase in the hormone-resistant cohort ( = 12). Mandatory tumor samples were obtained pre- and posttreatment (58% paired) with either up- or downregulation of ER observed in approximately 50% of posttreatment biopsies in the hormone-resistant, but not TNBC cohort. Combination epigenetic therapy was well tolerated, but our primary endpoint was not met. OC phase results suggest that some women benefit from epigenetic therapy and/or reintroduction of endocrine therapy beyond progression, but further study is needed. .

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/early/2016/12/
Web Search
http://dx.doi.org/10.1158/1078-0432.CCR-16-1729DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457329PMC
June 2017
164 Reads

Publication Analysis

Top Keywords

epigenetic therapy
20
breast cancer
12
combination epigenetic
12
endocrine therapy
8
primary endpoint
8
partial response
8
5-azacitidine entinostat
8
therapy
7
cohort
5
cancer
5
required patients
4
patients cohort
4
cohort continue
4
response required
4
design response
4
simon two-stage
4
two-stage design
4
null simon
4
continue accrual
4
women hormone-resistant
4

Similar Publications